) recently announced that the UK's National Institute for Health
and Care Excellence (NICE) has issued draft guidance where it
recommends Iluvien for the treatment of pseudophakic patients
with chronic diabetic macular edema (DME) considered
insufficiently responsive to available therapies.
The NICE Appraisal Committee said that Iluvien is effective in
the treatment of vision impairment associated with chronic DME in
patients who have insufficiently responded to available therapies
and also in pseudophakic chronic DME patients.
Once this recommendation becomes final, Iluvien will be
available in the UK to pseudophakic patients plus private pay and
privately insured patients. This is a revision from the initial
guidance issued by NICE in Jan 2013. It had earlier stated that
Iluvien is not cost effective for the treatment of chronic DME.
However, NICE now says that the drug meets the cost effective
benchmark for use in pseudophakic patients with chronic DME.
Iluvien is approved in the UK, Austria, France, Germany,
Portugal and Spain, while in Italy it has been recommended for
As per NICE, around 336,000 diabetes patients in the UK also
We note that pSivida had collaborated with
Alimera Sciences, Inc.
) to develop Iluvien for DME. The association between the two
companies dates back to Feb 2005.
In the first quarter of 2013, Alimera resubmitted a New Drug
Application (NDA) for Iluvien in response to the second Complete
Response Letter received in Nov 2011 from the US Food and Drug
Administration (FDA). The FDA will respond to the NDA by Oct 17,
pSivida Corp. carries a Zacks Rank #2 (Buy). Right now,
Jazz Pharmaceuticals Public Limited Company
Biogen Idec Inc.
) look more attractive with a Zacks Rank #1 (Strong Buy).
ALIMERA SCIENCE (ALIM): Get Free Report
BIOGEN IDEC INC (BIIB): Free Stock Analysis
JAZZ PHARMACEUT (JAZZ): Free Stock Analysis
PSIVIDA CORP (PSDV): Free Stock Analysis
To read this article on Zacks.com click here.